Mitsubishi Tanabe Pharma provides financial assistance to the SENSHIN Medical Research Foundation and the Japan Foundation for Applied Enzymology as a means of funding research in a broad range of fields including medicine, pharmaceuticals, agriculture, and the physical sciences. By providing support for the activities of both foundations, the Company works to promote research and provide information that benefits medical treatment and public health.

This foundation was established in 1968 with support from the former Yoshitomi Pharmaceutical Industries, Ltd. The foundation aims to contribute to the medical treatment and health of consumers. To that end, the foundation promotes advanced research in the fields of medicine and pharmacology, providing grants, commendations, etc., for pharmacopsychiatry research, hematological research, and circulatory research. In fiscal 2023, the foundation provided 105 grants worth a total amount of 134 million yen. For further information about the supported research and grant recipients, please refer to the foundation’s website. (https://www.smrf.or.jp) (Japanese language only)

This foundation was established in 1964 with support from the former Tanabe Seiyaku Co., Ltd. The foundation aims to contribute to the development of various fields in the life sciences in Japan by supporting research in a wide range of academic fields, from fundamental analysis of molecules affecting the regulation and maintenance of biological functions, such as enzymes, to applied research. To that end, the foundation provides support for enzyme research and grants for young researchers in four types. In fiscal 2023, the foundation provided 165 grants worth a total amount of 82.3 million yen. For further information about the supported research and grant recipients, please refer to the foundation’s website. (https://www.jfae.or.jp) (Japanese language only).

The Global Health Innovation Technology Fund (GHIT Fund) was established as Japan’s first public-private partnership to discover new drugs for infectious diseases that affect people in the developing world, such as malaria, tuberculosis, and neglected tropical diseases. We endorse the GHIT Funds objective of contributing to global health, and following the provision of financial support for the GHIT Fund first phase (fiscal 2013 - fiscal 2017) and second phase (fiscal 2018 - fiscal 2022), the Company is also providing financial support to the GHIT Fund for third phase (fiscal 2023 – 2027). Through the GHIT Fund, the Company provided its pharmaceutical compound library to research institutions to conduct joint research on drug exploration for malaria and neglected tropical diseases.
Moving forward, we will continue working to contribute to the health of people around the world, including contributions to the treatment of infectious diseases in the developing world.